QuantumFX (General Branding) EN

FXCess Review

Updated: August 2, 2026
FXCess
Views1125

Fast Facts

Contact Info and Support

Traffic information

CategoryMetricsMeaning
RatingsGlobal Rank405000
Country CodeFR
Country Rank30817
Category Rank183
Engagement metricsVisits60871
Bounce Rate0.3223
Pageviews per Visit5.81
Avg. Visit Duration214.65
Estimated monthly visitsApril 202659974
May 202654407
June 202660871
Top countriesFrance (FR)44.29%
United Kingdom (GB)11.05%
Morocco (MA)9.02%
Australia (AU)8.05%
Hungary (HU)5.73%
Traffic sourcesDirect60.36%
Referrals6.34%
Mail0.43%
Social-
Paid Referrals-
Search-
Top keywordsfxcess1360 ◦ $1.3 ◦ $4060
fxcess aolication ios130 ◦ $120
my.fxcess130 ◦ $120
api fxcess60 ◦ $110
fx acess affiliate80 ◦ $100

About FXCess

FXCess operates under the trade name of Notesco Int Limited, registered in Anguilla with registration number A000001800, and also refers to Notesco Limited, incorporated in Bermuda with registration number 51491, offering services via the domain fxcess.com ().

The broker is not authorised by the Spanish regulator Comisión Nacional del Mercado de Valores (CNMV) to provide investment services; a public warning (CNMV Warning_FXCESS) was issued on 2 March 2026 stating that FXCess is not authorised to offer services related to foreign currency transactions or other financial instruments under Spanish law ().

The Anguilla Financial Services Commission has issued an investor alert dated 6 January 2025 declaring that Notesco Int Limited trading as FXCess is not licensed, nor has ever been licensed, to conduct financial services business in derivatives, CFDs, forex, precious metals, or any related instruments ().

Pros and cons

Pros

  • No verifiable regulatory authorization exists; multiple regulators have issued warnings and alerts.

Cons

  • Operating without regulation from Spanish CNMV and Anguilla FSC.
  • Domain fxcess.com flagged as fraudulent by independent analysis citing regulatory warning dated 2 March 2026 ().
  • Regulatory and user-review sources describe lack of oversight, withdrawal issues, and deceptive practices ().

Page loaded in 635.00 ms